Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Dec;35(12):2041-2050.
doi: 10.1111/jgh.15156. Epub 2020 Jul 7.

Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis

Feng-Bin Lu  1 , Kenneth I Zheng  2 , Rafael S Rios  2 , Giovanni Targher  3 , Christopher D Byrne  4 , Ming-Hua Zheng  2   5   6
Affiliations
Meta-Analysis

Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis

Feng-Bin Lu et al. J Gastroenterol Hepatol. 2020 Dec.

Abstract

Background and aim: Lean non-alcoholic fatty liver disease (NAFLD) is a potentially metabolically unhealthy state that refers to NAFLD occurring in non-overweight/nonobese subjects. Yet its global epidemiology and metabolic characteristics are not extensively elucidated.

Methods: PubMed, EMBASE, Web of Science and Cochrane databases were searched for eligible studies until January 2020. Random-effects/fixed-effects models were used to estimate the global prevalence of lean NAFLD and to compare clinical characteristics among lean non-NAFLD, lean NAFLD, and overweight/obese NAFLD subjects. "Lean" NAFLD was defined by ethnic-specific body mass index measurements in the normal range. Meta-regression and subgroup analyses were performed to determine potential sources of heterogeneity.

Results: A total of 33 observational studies were included with 205 307 individuals from 14 countries. The global prevalence of lean NAFLD was 4.1% (95% confidence interval [CI]: 3.4-4.8%). In lean subjects, the prevalence of NAFLD was 9.7% (95% CI: 7.7-11.8%). The prevalence of lean NAFLD with diabetes, hypertension, metabolic syndrome, dyslipidemia, or central obesity was 0.6% (95% CI: 0.4-0.9%), 1.8% (95% CI: 1.2-2.5%), 1.4% (95% CI: 1.0-1.9%), 2.8% (95% CI: 1.9-3.7%), and 2.0% (95% CI: 1.6-2.4%), respectively. The prevalence of lean NAFLD showed an upward trend between 1988 and 2017. Asian individuals had the highest prevalence of lean NAFLD (4.8%, 95% CI: 4.0-5.6%). Middle-aged people (45-59 years old) had the highest prevalence of lean NAFLD (4.4%, 95% CI: 3.2-5.5%). The prevalence of metabolic complications in lean non-NAFLD, lean NAFLD, and overweight/obese NAFLD groups increased sequentially.

Conclusions: Lean NAFLD occurs with metabolic complications and is not an uncommon condition. The highest prevalence of lean NAFLD occurs in middle-aged individuals of Asian countries.

Keywords: Body mass index; Epidemiology; Lean NAFLD; Meta-analysis; Metabolism; Non-overweight.

PubMed Disclaimer

References

    1. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357.
    1. Eslam M, Newsome PN, Sarin SK et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J. Hepatol. 2020 Apr 8:S0168-8278(20)30201-4. https://doi.org/10.1016/j.jhep.2020.03.039.
    1. Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J. Hepatol. 2020; 72: 785-801.
    1. Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metab: Clin Exp 2020: 154170.
    1. Byrne CD, Targher G. NAFLD: a multisystem disease. J. Hepatol. 2015; 62: S47-S64.